Fullerene Therapeutics Inc. is ready to take C3 to the next level – clinical trials. We believe a high probability of success in human FDA Phase I clinical trials exists:

  • Low likelihood of compound accumulating in humans due to multiple routes of clearance
  • The C3 molecule is excreted from the body intact
  • C3 compound has a plasma half-life of 8 hours, and has high renal and hepatic clearance
  • C3 is not metabolized in mammals
The Company has an active private placement memorandum for investors that meet SEC qualifying regulations. If interested, please contact us for the appropriate paperwork.

Copyright 2019 Fullerene Therapeutics, Inc.
No part of the contents of this web site may be 
reproduced without express written permission.